Glaucomas: Uveitic Glaucoma

Chapter
First Online:

Abstract

Making a correct diagnosis of the etiology of intraocular inflammation is the first and most important step in the management of uveitic glaucoma.

Keywords

Uveitic glaucoma Steroid-induced glaucoma Intraocular inflammation Trabeculectomy Baerveldt shunt Ahmed shunt Cyclodestructive procedures Laser trabeculoplasty Laser peripheral iridotomy Prostaglandin analogues 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Alward WL. The genetics of open-angle glaucoma: the story of GLC1A and myocilin. Eye (Lond). 2000;14(Pt 3B):429–36.CrossRefGoogle Scholar
  2. 2.
    Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70:492–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Barton K, Feuer WJ, Budenz DL, Schiffman J, Costa VP, Godfrey DG, Buys YM, Ahmed Baerveldt Comparison Study Group. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2014;121:1547–1557.e1541.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J, Ahmed Baerveldt Comparison Study Group. The Ahmed Baerveldt Comparison Study methodology, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011;118:435–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol. 1962;68:742–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79:1012–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Ceballos EM, Beck AD, Lynn MJ. Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma. 2002;11:189–96.CrossRefPubMedGoogle Scholar
  9. 9.
    Ceballos EM, Parrish II RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology. 2002;109:2256–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen J, Cohn RA, Lin SC, Cortes AE, Alvarado JA. Endoscopic photocoagulation of the ciliary body for treatment of refractory glaucomas. Am J Ophthalmol. 1997;124:787–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013;120:2232–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Christakis PG, Tsai JC, Zurakowski D, Kalenak JW, Cantor LB, Ahmed II. The Ahmed Versus Baerveldt study: design, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011;118:2172–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Clark AF, Wilson K, de Kater AW, Allingham RR, McCartney MD. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995;36:478–89.PubMedGoogle Scholar
  14. 14.
    Epstein RJ, Brown SV, Konowal A. Endothelial changes associated with topical dorzolamide do appear to be significant. Arch Ophthalmol. 2004;122:1089, author reply 1090.CrossRefPubMedGoogle Scholar
  15. 15.
    Fingert JH, Clark AF, Craig JE, Alward WL, Snibson GR, McLaughlin M, Tuttle L, Mackey DA, Sheffield VC, Stone EM. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:145–52.PubMedGoogle Scholar
  16. 16.
    Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Freedman SF, Rodriguez-Rosa RE, Rojas MC, Enyedi LB. Goniotomy for glaucoma secondary to chronic childhood uveitis. Am J Ophthalmol. 2002;133:617–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Galor A, Margolis R, Brasil OM, Perez VL, Kaiser PK, Sears JE, Lowder CY, Smith SD. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Gil-Carrasco F, Salinas-VanOrman E, Recillas-Gispert C, Paczka JA, Gilbert ME, Arellanes-Garcia L. Ahmed valve implant for uncontrolled uveitic glaucoma. Ocul Immunol Inflamm. 1998;6:27–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Goulet III RJ, Phan AD, Cantor LB, WuDunn D. Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant. Ophthalmology. 2008;115:1141–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Ho CL, Wong EY, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. Arch Ophthalmol. 2004;122:838–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Jampel HD, Jabs DA, Quigley HA. Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. Am J Ophthalmol. 1990;109:168–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Jeng KW, Fine HF, Wheatley HM, Roth D, Connors DB, Prenner JL. Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. Retina. 2014;34:1990–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Jones III R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–7.PubMedGoogle Scholar
  25. 25.
    Kafkala C, Hynes A, Choi J, Topalkara A, Foster CS. Ahmed valve implantation for uncontrolled pediatric uveitic glaucoma. J AAPOS. 2005;9:336–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20:407–16.CrossRefGoogle Scholar
  27. 27.
    Kim J, Allingham RR, Hall J, Klitzman B, Stinnett S, Asrani S. Clinical experience with a novel glaucoma drainage implant. J Glaucoma. 2014;23:e91–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin North Am. 2002;15:375–87, viii.CrossRefPubMedGoogle Scholar
  29. 29.
    Konowal A, Morrison JC, Brown SV, Cooke DL, Maguire LJ, Verdier DV, Fraunfelder FT, Dennis RF, Epstein RJ. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Lin S. Endoscopic cyclophotocoagulation. Br J Ophthalmol. 2002;86:1434–8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lin SC. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma. 2008;17:238–47.CrossRefPubMedGoogle Scholar
  32. 32.
    Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, LaBree L, Heuer DK. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994;101:1456–63, discussion 1463–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Lo WR, Rowlette LL, Caballero M, Yang P, Hernandez MR, Borras T. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci. 2003;44:473–85.CrossRefPubMedGoogle Scholar
  34. 34.
    Moorthy RS, Mermoud A, Baerveldt G, Minckler DS, Lee PP, Rao NA. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361–94.CrossRefPubMedGoogle Scholar
  35. 35.
    Murphy CC, Burnett CA, Spry PG, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2003;87:1252–7.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Nagataki S, Mishima S. Aqueous humor dynamics in glaucomato-cyclitic crisis. Invest Ophthalmol. 1976;15:365–70.PubMedGoogle Scholar
  37. 37.
    Papadaki TG, Zacharopoulos IP, Pasquale LR, Christen WB, Netland PA, Foster CS. Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol. 2007;144:62–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Park UC, Ahn JK, Park KH, Yu HG. Phacotrabeculectomy with mitomycin C in patients with uveitis. Am J Ophthalmol. 2006;142:1005–12.CrossRefPubMedGoogle Scholar
  39. 39.
    Puska PM, Tarkkanen AH. Transscleral red laser cyclophotocoagulation for the treatment of therapy-resistant inflammatory glaucoma. Eur J Ophthalmol. 2007;17:550–6.PubMedGoogle Scholar
  40. 40.
    Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur J Ophthalmol. 2006;16:756–7.PubMedGoogle Scholar
  41. 41.
    Saccà S, Pascotto A, Siniscalchi C, Rolando M. Ocular complications of latanoprost in uveitic glaucoma: three case reports. J Ocul Pharmacol Ther. 2001;17:107–13.CrossRefPubMedGoogle Scholar
  42. 42.
    Schlote T, Derse M, Zierhut M. Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases. Br J Ophthalmol. 2000;84:999–1003.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Schwartz KS, Lee RK, Gedde SJ. Glaucoma drainage implants: a critical comparison of types. Curr Opin Ophthalmol. 2006;17:181–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Skolnick CA, Fiscella RG, Tessler HH, Goldstein DA. Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitis. Am J Ophthalmol. 2000;129:363–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668–72.CrossRefPubMedGoogle Scholar
  46. 46.
    Spencer NA, Hall AJ, Stawell RJ. Nd:YAG laser iridotomy in uveitic glaucoma. Clin Experiment Ophthalmol. 2001;29:217–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Sung VC, Barton K. Management of inflammatory glaucomas. Curr Opin Ophthalmol. 2004;15:136–40.CrossRefPubMedGoogle Scholar
  48. 48.
    Syed HM, Law SK, Nam SH, Li G, Caprioli J, Coleman A. Baerveldt-350 implant versus Ahmed valve for refractory glaucoma: a case-controlled comparison. J Glaucoma. 2004;13:38–45.CrossRefPubMedGoogle Scholar
  49. 49.
    Tajika T, Waki M, Tsuzuki M, Kida T, Sakaki H. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011;27:29–34.CrossRefPubMedGoogle Scholar
  50. 50.
    Towler HM, McCluskey P, Shaer B, Lightman S. Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology. 2000;107:1822–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Tsai JC, Johnson CC, Kammer JA, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon. Ophthalmology. 2006;113:913–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26:170–5.PubMedGoogle Scholar
  54. 54.
    Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629–67.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual SciencesDalhousie UniversityHalifaxCanada
  2. 2.Department of Ophthalmology and Visual SciencesUniversity of IowaIowa CityUSA

Personalised recommendations